Lars H. Genieser, Ph.D.

Lars H. Genieser, Ph.D.

Practice Areas
Education
  • Georgetown University Law Center, J.D., 2006
  • Eindhoven University of Technology, The Netherlands, NSF-NATO Postdoctoral Fellow, 1998
  • Massachusetts Institute of Technology, Ph.D., 1997
  • University of Düsseldorf, German Academic Exchange Service Scholar, 1990
  • Princeton University, B.S., summa cum laude, 1989
Bar Admissions
  • Virginia
  • District of Columbia
  • U.S. Patent and Trademark Office

Lars H. Genieser, Ph.D. Partner

Philadelphia: 215.965.1236   F: 215.965.1331   E: lgenieser@panitchlaw.com

Dr. Lars Genieser is a registered patent attorney who focuses his patent prosecution practice on pharmaceutical, chemical, material science, and medical technologies for domestic and foreign clients. He effectively develops and implements worldwide patent protection strategies.

His broad experience in industry and academia enables him to anticipate and develop solutions to challenges for technology-driven clients. Lars pursues and obtains patents and manages patent portfolios for pharmaceuticals, epigenetic systems, antibodies, vaccines, proteomic systems, controlled and targeted pharmaceutical release systems, novel polymers, coatings, surfactant systems, polymer-metal hybrid nanoparticles, quantum dots, nanostructured materials, organometallic compounds, catalysts, plasma generation systems and processing of semi-noble metal, electrochemical systems, water purification, cosmetics, stents, surgical instruments, analytical devices, and environmental remediation systems.  For example, he developed and manages a complex international patent portfolio for a successful new cancer treatment drug. 

Lars is experienced in successfully appealing patent application examinations to the U.S. Patent and Trademark Office (USPTO) Patent Trial and Appeal Board (PTAB), responding to and prevailing over foreign post-grant patent Oppositions, obtaining Patent Term Extensions in the U.S. and abroad, and preparing patent licenses. He brings a practical and business-oriented approach to counseling clients on all stages of the patenting and technology-monetization process.

Lars received his bachelor's degree summa cum laude in chemical engineering from Princeton University and his Ph.D. from the Massachusetts Institute of Technology. He conducted postdoctoral research at the Eindhoven University of Technology in the Netherlands as an NSF-Nato Postdoctoral Fellow. Lars earned his J.D. degree from Georgetown University Law Center. He is a member of the Virginia and District of Columbia Bars and is registered to practice before the U.S. Patent and Trademark Office.   

Lars is fluent in German and reads French and Dutch. He was named a Washington, D.C.  "Rising Star" by Thomson Reuters for 2014 to 2016.

The Super Lawyers® list is issued by Thomson Reuters under criteria applied by Super Lawyers®. A description of the selection methodology can be found at http://www.superlawyers.com/about/selection_process.html.

Articles & Presentations

L.H. Genieser & M.E. Jung (Aug. 2017) From Discovery to Blockbuster: Patent Strategies for Novel Therapeutics.California NanoSystems Institute (CNSI) at Univ. Calif. Los Angeles (UCLA).

L.H. Genieser (Mar. 2013) Realizing Value Through Patents. Webinar for LARTA Institute.

L.H. Genieser (Aug. 2012) Veränderung im U.S. Patentrecht Veranlasst Durch das "American Invents Act" von 2011. German language presentation, IPAL, Berlin, Germany.

L.H. Genieser & C.E. McCann (Sept. 2012) Obtaining, Challenging and Enforcing Pharmaceutical Patents Under the America Invents Act.  Pharma. Pat. Analyst 1(4), 415-426.

Memberships

  • American Bar Association
  • American Intellectual Property Law Association
  • American Chemical Society
  • Sigma Ix Honorary Scientific Research Society

Articles & Presentations

Panitch Schwarze Welcomes Lars H. Genieser // July 10, 2018
Panitch Schwarze is pleased to announce that registered patent attorney Dr. Lars Genieser has joined the firm as a partner. He focuses his practice on pharmaceutical, chemical, material science, and medical technologies for domestic and foreign clients. Read more

Email Disclaimer

Sending an email to our office does not create an attorney-client relationship, and none will be formed unless there is an expressed agreement between the firm and the client. Thus, we strongly advise against sending confidential or privileged information to us until you can establish such a relationship. Furthermore, we advise against sending privileged or confidential information through email at all, since we can in no way ensure the security of your email. In fact, neither this website nor the email system involved is encrypted, so you should not assume that your email is confidential. We cannot guarantee that someone else will not see it.

Do you agree to this Email Disclaimer?

I Agree I Do Not Agree